 NEW YORK, Nov. 03, 2022 GLOBE NEWSWIRE -- SELLAS Life Sciences Group, Inc. NASDAQ: SLS SELLAS or the Company, a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will present data relating to its highly selective CDK9 inhibitor, GFH009, during two poster presentations at the American Society of Hematology ASH Annual Meeting being held on December 10-13, 2022 in New Orleans, Louisiana. The meeting will also take place virtually. 